{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:46:13Z","timestamp":1791992773406,"version":"4.4.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"abstract":"<jats:p>This survey study with a nationally representative sample evaluates whether individuals who initiate glucagon-like peptide-1 receptor agonists (GLP-1 RAs) report reducing alcohol consumption after starting the drug.<\/jats:p>","DOI":"10.1001\/jamapsychiatry.2026.3242","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:00:33Z","timestamp":1791990033000},"source":"Crossref","is-referenced-by-count":0,"title":["Patient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation"],"prefix":"10.1001","author":[{"given":"Lori","family":"Uscher-Pines","sequence":"first","affiliation":[{"name":"Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sousa","sequence":"additional","affiliation":[{"name":"RAND Corporation, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa B.","family":"Busch","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"McLean Hospital, Belmont, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ateev","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Muzyk","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Hodgkin","sequence":"additional","affiliation":[{"name":"Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Greenfield","sequence":"additional","affiliation":[{"name":"McLean Hospital, Belmont, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiden A.","family":"Huskamp","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"13","key":"yld260017r3","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 receptor agonists.","volume":"394","author":"Rosen","year":"2026","journal-title":"N Engl J Med"},{"key":"yld260017r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102920","article-title":"Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.","volume":"78","author":"Subhani","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"yld260017r6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"8","key":"yld260017r7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(25)00134-7","article-title":"GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease.","volume":"10","author":"Singal","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"yld260017r9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11606-009-0928-6","article-title":"Primary care validation of a single-question alcohol screening test.","volume":"24","author":"Smith","year":"2009","journal-title":"J Gen Intern Med"},{"key":"yld260017r1","unstructured":"US Centers for Disease Control and Prevention. Facts about US deaths from excessive alcohol use. August 6, 2024. Accessed September 9, 2026. http:\/\/cdc.gov\/alcohol\/facts-stats\/index.html"},{"key":"yld260017r2","unstructured":"World Health Organization. No level of alcohol consumption is safe for our health. January 4, 2023. Accessed September 9, 2026. https:\/\/who.int\/europe\/news\/item\/04-01-2023-no-level-of-alcohol-consumption-is-safe-for-our-health"},{"key":"yld260017r4","doi-asserted-by":"crossref","unstructured":"Bozick? R, Donofry? SD, Ranca\u00f1o? KM. New weight loss drugs: GLP-1 agonist use and side effects in the United States. RAND Corporation. August 6, 2025. Accessed September 9, 2026. https:\/\/www.rand.org\/pubs\/research_reports\/RRA4153-1.html","DOI":"10.7249\/rhq-13-01-03"},{"key":"yld260017r8","doi-asserted-by":"crossref","unstructured":"Pollard? MS, Baird? MD. The RAND American Life Panel: technical description. RAND Corporation. July 26, 2017. Accessed September 9, 2026. https:\/\/www.rand.org\/pubs\/research_reports\/RR1651.html","DOI":"10.7249\/RR1651"},{"key":"yld260017r10","unstructured":"Serres? C. \u2018I feel reborn\u2019: a Providence program is using GLP-1 drugs to free people from addiction. February 12, 2026. Accessed September 9, 2026. https:\/\/www.bostonglobe.com\/2026\/02\/12\/metro\/glp-1-semaglutide-addiction-providence-rhode-island\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2854926\/jamapsychiatry_uscherpines_2026_ld_260017_1790709817.25484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:00:37Z","timestamp":1791990037000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2854926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.3242","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,14]]}}}